Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma

An analysis of 83 cases

Shou-Ching Tang, L. Visser, B. Hepperle, J. Hanson, S. Poppema

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Purpose: The goal of this study was to assess the prognostic significance of a rearrangement of the major breakpoint region of the bcl-2 gene and/or expression of bcl-2 protein in diffuse large-cell lymphomas of B-cell origin. Patients and Methods: All 83 patients diagnosed at the Cross Cancer Institute between 1987 and 1992 with malignant lymphoma (ML), diffuse large-cell ML noncleaved-cell ML or cleaved-cell ML, or with diffuse large-cell immunoblastic ML were studied. bcl-2 rearrangement was identified by a polymerase chain reaction technique. This technique detects the approximately 60% of rearrangements involving the major breakpoint region bcl-2 gene (bcl- 2-MBR). bcl-2 protein expression was studied by immunohistochemistry. Results: More than 66% of the cases expressed bcl-2 protein, whereas 18% had a detectable bcl-2-MBR gene rearrangement. Overall, cases with bcl-2-MBR rearrangement had shorter disease-free periods. Cases with nodal and extranodal presentation had a similar frequencies of bcl-2-MBR rearrangement; however, the disease-free period of patients with extranodal presentation and bcl-2-MBR rearrangement was significantly shorter than that of those without rearrangement. Conclusion: bcl-2 protein is frequently expressed in diffuse large-cell lymphomas, but does not influence prognosis. The bcl-2-MBR gene rearrangement may possibly be associated with a shorter disease-free period, particularly in the specific setting of a lymphoma with extranodal presentation.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalJournal of Clinical Oncology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1994

Fingerprint

bcl-2 Genes
Gene Rearrangement
Non-Hodgkin's Lymphoma
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Proteins
Large-Cell Immunoblastic Lymphoma
B-Cell Lymphoma
Immunohistochemistry
Gene Expression
Polymerase Chain Reaction
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma : An analysis of 83 cases. / Tang, Shou-Ching; Visser, L.; Hepperle, B.; Hanson, J.; Poppema, S.

In: Journal of Clinical Oncology, Vol. 12, No. 1, 01.01.1994, p. 149-154.

Research output: Contribution to journalArticle

Tang, Shou-Ching ; Visser, L. ; Hepperle, B. ; Hanson, J. ; Poppema, S. / Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma : An analysis of 83 cases. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 1. pp. 149-154.
@article{3120fe2166984bdd94dc2b192180a7d8,
title = "Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases",
abstract = "Purpose: The goal of this study was to assess the prognostic significance of a rearrangement of the major breakpoint region of the bcl-2 gene and/or expression of bcl-2 protein in diffuse large-cell lymphomas of B-cell origin. Patients and Methods: All 83 patients diagnosed at the Cross Cancer Institute between 1987 and 1992 with malignant lymphoma (ML), diffuse large-cell ML noncleaved-cell ML or cleaved-cell ML, or with diffuse large-cell immunoblastic ML were studied. bcl-2 rearrangement was identified by a polymerase chain reaction technique. This technique detects the approximately 60{\%} of rearrangements involving the major breakpoint region bcl-2 gene (bcl- 2-MBR). bcl-2 protein expression was studied by immunohistochemistry. Results: More than 66{\%} of the cases expressed bcl-2 protein, whereas 18{\%} had a detectable bcl-2-MBR gene rearrangement. Overall, cases with bcl-2-MBR rearrangement had shorter disease-free periods. Cases with nodal and extranodal presentation had a similar frequencies of bcl-2-MBR rearrangement; however, the disease-free period of patients with extranodal presentation and bcl-2-MBR rearrangement was significantly shorter than that of those without rearrangement. Conclusion: bcl-2 protein is frequently expressed in diffuse large-cell lymphomas, but does not influence prognosis. The bcl-2-MBR gene rearrangement may possibly be associated with a shorter disease-free period, particularly in the specific setting of a lymphoma with extranodal presentation.",
author = "Shou-Ching Tang and L. Visser and B. Hepperle and J. Hanson and S. Poppema",
year = "1994",
month = "1",
day = "1",
doi = "10.1200/JCO.1994.12.1.149",
language = "English (US)",
volume = "12",
pages = "149--154",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma

T2 - An analysis of 83 cases

AU - Tang, Shou-Ching

AU - Visser, L.

AU - Hepperle, B.

AU - Hanson, J.

AU - Poppema, S.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Purpose: The goal of this study was to assess the prognostic significance of a rearrangement of the major breakpoint region of the bcl-2 gene and/or expression of bcl-2 protein in diffuse large-cell lymphomas of B-cell origin. Patients and Methods: All 83 patients diagnosed at the Cross Cancer Institute between 1987 and 1992 with malignant lymphoma (ML), diffuse large-cell ML noncleaved-cell ML or cleaved-cell ML, or with diffuse large-cell immunoblastic ML were studied. bcl-2 rearrangement was identified by a polymerase chain reaction technique. This technique detects the approximately 60% of rearrangements involving the major breakpoint region bcl-2 gene (bcl- 2-MBR). bcl-2 protein expression was studied by immunohistochemistry. Results: More than 66% of the cases expressed bcl-2 protein, whereas 18% had a detectable bcl-2-MBR gene rearrangement. Overall, cases with bcl-2-MBR rearrangement had shorter disease-free periods. Cases with nodal and extranodal presentation had a similar frequencies of bcl-2-MBR rearrangement; however, the disease-free period of patients with extranodal presentation and bcl-2-MBR rearrangement was significantly shorter than that of those without rearrangement. Conclusion: bcl-2 protein is frequently expressed in diffuse large-cell lymphomas, but does not influence prognosis. The bcl-2-MBR gene rearrangement may possibly be associated with a shorter disease-free period, particularly in the specific setting of a lymphoma with extranodal presentation.

AB - Purpose: The goal of this study was to assess the prognostic significance of a rearrangement of the major breakpoint region of the bcl-2 gene and/or expression of bcl-2 protein in diffuse large-cell lymphomas of B-cell origin. Patients and Methods: All 83 patients diagnosed at the Cross Cancer Institute between 1987 and 1992 with malignant lymphoma (ML), diffuse large-cell ML noncleaved-cell ML or cleaved-cell ML, or with diffuse large-cell immunoblastic ML were studied. bcl-2 rearrangement was identified by a polymerase chain reaction technique. This technique detects the approximately 60% of rearrangements involving the major breakpoint region bcl-2 gene (bcl- 2-MBR). bcl-2 protein expression was studied by immunohistochemistry. Results: More than 66% of the cases expressed bcl-2 protein, whereas 18% had a detectable bcl-2-MBR gene rearrangement. Overall, cases with bcl-2-MBR rearrangement had shorter disease-free periods. Cases with nodal and extranodal presentation had a similar frequencies of bcl-2-MBR rearrangement; however, the disease-free period of patients with extranodal presentation and bcl-2-MBR rearrangement was significantly shorter than that of those without rearrangement. Conclusion: bcl-2 protein is frequently expressed in diffuse large-cell lymphomas, but does not influence prognosis. The bcl-2-MBR gene rearrangement may possibly be associated with a shorter disease-free period, particularly in the specific setting of a lymphoma with extranodal presentation.

UR - http://www.scopus.com/inward/record.url?scp=0028137678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028137678&partnerID=8YFLogxK

U2 - 10.1200/JCO.1994.12.1.149

DO - 10.1200/JCO.1994.12.1.149

M3 - Article

VL - 12

SP - 149

EP - 154

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -